Canadian Meds |
Policy | Legal
Terms | Meds Index
Generic - ranitidine
Drug class - H2 antagonists
Main indication - GERD, conditions where acid enters esophagus
Administration type - oral intake
Manufacturer - Mylan, Sivem Pharmaceuticals
Pregnancy category - no proven risk in humans (taken with caution)
FDA records - starting from 1975
Ranitidine, based on the the active substance of the same name, aims at a reduction of the gastric juices amount caused by stretching of the stomach by food loads, as well as the action of certain hormones and biogenic stimulants, for example histamine, gastrin, acetylcholine, caffeine and pentagastrin. In the US the preparation is available by prescription only; in the US the drug is mostly available by Sivem Pharmaceuticals and Mylan Pharmaceuticals. The ingredient has been first mentioned in the FDA registry in 1975, since then a number of ‘new formulation’ records has been added.
When using Ranitidine enhanced protective mechanisms of gastric mucosa is provided, decreasing the amount of HCl in the gastric juice, while not substantially suppressing the ‘liver’ enzymes and not altering the production of mucus. Ranitidine application promotes healing of mucosal damage that is associated with exposure to HCl. The healing effect of the drug is achieved due to increased formation of gastric mucus. The therapeutic dose of Ranitidine, according to the instructions, equals 150 mg, consumed each 8-12 hours to suppress gastric acid secretion.
Ranitidine is released in the following dosage form:
• Tablets containing 0.15 and 0.3 g of active substance, 10, 20, 30 or 100 units per pack;
• Solution for injection, in 2 ml ampoules.
Indications for use
According to the insert Ranitidine is used in the following cases:
• stomach ulcers and 12 duodenal ulcer in the acute stage;
• inflammation of the esophagus on the background of the damage of the integrity of its mucosa (erosive esophagitis);
• inflammation of the esophagus, which is caused by throwing in gastric contents;
• combination benign tumor of the pancreas and stomach ulcers (Zollinger-Ellison syndrome);
• Symptomatic ulcers, including the rapidly developing stomach ulcers and 12 duodenal ulcers, which have arisen as a result of stress, medication or certain diseases of other organs.
The preparation is oftentimes included in the preventive treatment in case of:
• damage of the upper gastrointestinal tract;
• acute forms of ulcers;
• prevention of gastric juice from entering the airway during surgical anesthesia.
The medication should not be applied in the following cases:
• during pregnancy;
• in case of hypersensitivity to any substances of the drug;
• during lactation;
• The age of 14 years and less.
Ranitidine is prescribed with caution in those patients with violations of renal excretory function.
How to take the preparation
Ranitidine is prescribed for adults at 0.15g dosage two times per day or with one intake (0.3 g) once before bedtime. The duration of treatment typically not 2 months.
Using the drug for the prevention of relapse of peptic ulcer appoint one tablet of Ranitidine (0.15 g) is taken orally at bedtime during up to 12 months (in this case regular endoscopic control is required).
In the case of Zollinger-Ellison disease the medication is appointed at 0.15 g dosage three times a day, but if necessary, the daily dose is increased to 2-3 tablets. To prevent bleeding and stress ulceration, Ranitidine is used in intravenous or intramuscular injection of 0.05-0.1g every 6-8 hours. When using Ranitidine in children aged 14-18 years, the drug is prescribed twice a day at 0.15g dosage. In renal failure with a creatinine level of 3.3 mg/100 ml ranitidine administered at the rate of 0.075 g twice a day.
© 2003-2017 Rx Meds Canada . All Rights Reserved